Takeda: Crohn Disease trials

The registry lists 85 Crohn Disease studies with Takeda as lead sponsor. 13 are open to participants now and 37 have results posted.

Phase 1 3Phase 2 14Phase 3 24Phase 4 10No phase 35(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study of Zasocitinib (TAK-279) in Adults With Active Crohn's DiseaseRecruitingNCT07403968Phase 2
• Expanded Access to Vedolizumab for Children and Teenagers With Ulcerative Colitis or Crohn's Disease in the USAAvailableNCT06856135
• A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD)RecruitingNCT06764615Phase 2
• A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community SettingRecruitingNCT06581328Phase 4
• A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)RecruitingNCT06405087Phase 3
• A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's DiseaseRecruitingNCT06233461Phase 2
• A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's DiseaseRecruitingNCT06227910Phase 3
• A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's DiseaseRecruitingNCT06100289Phase 3
• A Study of Vedolizumab in Adult Participants With Moderate to Severe Crohn's DiseaseRecruitingNCT05837897Phase 3
• A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)RecruitingNCT05442567Phase 3
• A Study of Vedolizumab SC Given to Adults With Moderate to Severe Ulcerative Colitis or Crohn's Disease in South KoreaRecruitingNCT05428345
• A Survey of Darvadstrocel in People With Crohn's DiseaseRecruitingNCT05113095
• A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)RecruitingNCT04779320Phase 3
• A Study of the Quality of Life in Adults With Crohn's Disease With Complex Perianal FistulasCompletedNCT04876690Results posted
• A Study of Moderate to Severe Inflammatory Bowel Disease, Including Ulcerative Colitis (UC) and Crohn's Disease (CD)CompletedNCT04873700Results posted
• A Study of Vedolizumab in People With Ulcerative Colitis and Crohn's DiseaseCompletedNCT04804540Phase 4Results posted
• A Study of Intravenous Vedolizumab Administered Every 4 Weeks in Japanese Participants With Moderate to Severe Ulcerative Colitis or Crohn's DiseaseActive, not recruitingNCT04738942Phase 3Results posted
• A Study of Darvadstrocel for Treating Complex Perianal Fistulas in Children and Teenagers With Crohn's DiseaseTerminatedNCT04701411Phase 3Results posted
• Study of Relationship Between Vedolizumab Therapeutic Drug Monitoring, Biomarkers of Inflammation and Clinical OutcomesCompletedNCT04567628Results posted
• A Study of Darvadstrocel in Adults With Crohn's Disease and Complex Perianal FistulaTerminatedNCT04118088Phase 4Results posted
• Long-term Follow-up Study With Darvadstrocel in the Treatment of Complex Perianal FistulaCompletedNCT04075825Phase 3Results posted
• Perianal Fistula (PAF) Validation and Burden of Illness StudyCompletedNCT03981939Results posted
• A Study of TAK-018 in Preventing the Recurrence of Crohn's Disease After SurgeryTerminatedNCT03943446Phase 2Results posted
• A Study to Observe Vedolizumab and Anti-tumour Necrosis Factors (Anti-TNFs) Outcomes in Real-world Biologic Ulcerative Colitis (UC) and Crohn's Disease (CD) ParticipantsCompletedNCT03710486Results posted
• Efficacy and Safety Study of Ontamalimab as Maintenance Treatment in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 307)TerminatedNCT03627091Phase 3Results posted
• Efficacy and Safety Study of Ontamalimab as Induction Therapy in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 306)TerminatedNCT03566823Phase 3Results posted
• Efficacy and Safety Study of Ontamalimab as Induction Therapy in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 305)TerminatedNCT03559517Phase 3Results posted
• A Study to Evaluate Disease Control and Treatment Pattern in Participants With Moderate to Severe Inflammatory Bowel Disease (IBD) in Real Life PracticeCompletedNCT03532932Results posted
• A Study to Evaluate Disease Control, Treatment Patterns, Burden of Disease and Quality of Life in Participants With Moderate to Severe Inflammatory Bowel Disease (IBD)CompletedNCT03488030Results posted
• A Study to Determine the Pharmacokinetics (PK) of Single Intravenous (IV) Dose of Vedolizumab 300 Milligram (mg) in Healthy Adult Chinese ParticipantsCompletedNCT03329209Phase 1Results posted
• A Safety Extension Study of Ontamalimab in Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)CompletedNCT03283085Phase 3Results posted
• Study to Assess Efficacy and Safety of Cx601, Adult Allogeneic Expanded Adipose-derived Stem Cells (eASC) for the Treatment of Complex Perianal Fistula(s) in Participants With Crohn's Disease (CD)CompletedNCT03279081Phase 3Results posted
• Vedolizumab Intravenous (IV) Compared to Placebo in Chinese Participants With Crohn's Disease.CompletedNCT03234907Phase 3Results posted
• Long-term Safety With Vedolizumab Intravenous (IV) in Pediatric Participants With Ulcerative Colitis (UC) or Crohn's Disease (CD)CompletedNCT03196427Phase 2Results posted
• Vedolizumab IV in Pediatric Participants With Ulcerative Colitis (UC) or Crohn's Disease (CD)CompletedNCT03138655Phase 2Results posted
• Triple Combination Therapy in High Risk Crohn's Disease (CD)CompletedNCT02764762Phase 4Results posted
• Extended Access Program of Vedolizumab IV in Ulcerative Colitis and Crohn's DiseaseTerminatedNCT02743806Phase 4Results posted
• Vedolizumab IV 300 mg in the Treatment of Fistulizing Crohn's DiseaseCompletedNCT02630966Phase 4Results posted
• A Study of Long-term Effects of Vedolizumab Subcutaneous in Adults With Ulcerative Colitis and Crohn's DiseaseCompletedNCT02620046Phase 3Results posted
• Efficacy and Safety of Vedolizumab Subcutaneous (SC) as Maintenance Therapy in Crohn's Disease (CD)CompletedNCT02611817Phase 3Results posted
• Postmarketing Vedolizumab Milk-Only Lactation Study in Lactating Women With Active Ulcerative Colitis or Crohn's DiseaseCompletedNCT02559713Phase 4Results posted
• Effect of Intravenous (IV) Vedolizumab on Mucosal Healing in Crohn's DiseaseCompletedNCT02425111Phase 3Results posted
• Phase III Study of MLN0002 (300 mg) in Treatment of Crohn's DiseaseCompletedNCT02038920Phase 3Results posted
• Evaluate PF-00547659 On Cerebrospinal Fluid Lymphocytes In Volunteers With Crohn's Disease Or Ulcerative Colitis Who Failed Or Did Not Tolerate Anti-TNFsCompletedNCT01387594Phase 1Results posted
• A Study To Monitor Long-Term Treatment With PF-00547659CompletedNCT01298492Phase 2Results posted
• Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's DiseaseCompletedNCT01276509Phase 2Results posted
• Study of Vedolizumab in Patients With Moderate to Severe Crohn's DiseaseCompletedNCT01224171Phase 3Results posted
• An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's DiseaseCompletedNCT00790933Phase 3Results posted
• Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's DiseaseCompletedNCT00783692Phase 3Results posted
• Long Term Safety of Vedolizumab (MLN0002) in Patients With Ulcerative Colitis and Crohn's DiseaseCompletedNCT00619489Phase 2Results posted
• A Study on Infections in Adults With Ulcerative Colitis/Crohn's DiseaseWithdrawnNCT07250815
• A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's DiseaseActive, not recruitingNCT06045754Phase 4
• A Study in Adults With Inflammatory Bowel Disease (IBD) Receiving Vedolizumab in the Patient Support Program (PSP) in BrazilCompletedNCT05626088
• A Study of Vedolizumab and Biologic Agents in Participants With Inflammatory Bowel Disease (IBD)CompletedNCT05596422
• A Study in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) Receiving Vedolizumab in Real-World Practice in PolandCompletedNCT05384080
• A Study of Vedolizumab in Adults With Crohn's Disease (CD)CompletedNCT05192863
• A Study of Real-World Outcomes of People With Crohn's Disease (CD)CompletedNCT05056441
• A Study in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) Receiving Vedolizumab in Real-World Practice in SwitzerlandCompletedNCT04989907
• A Study to Check How Often People Treated With Darvadstrocel for Crohn's Disease Are Diagnosed With CancerWithdrawnNCT04971525
• A Study on How Vedolizumab is Given and the Outcomes for Adults With Inflammatory Bowel Disease (VARIETY-Belgium)CompletedNCT04959851
• A Study of Surgical Interventions in Fistulizing ConditionsCompletedNCT04940611
• A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in Real-World PracticeCompletedNCT04890262
• A Study on Administration Choices of Vedolizumab and Outcomes for Adults With Inflammatory Bowel Disease (IBD) (VARIETY - CROATIA AND SLOVENIA)CompletedNCT04885920
• A Study of Vedolizumab in Adults in Real-World PracticeCompletedNCT04872491
• A Study Using Artificial Intelligence to Identify Adults With Complex Perianal Fistulas Associated With Crohn's DiseaseCompletedNCT04844593
• A Study of CDPATH™ to Help Manage and Treat Crohn's DiseaseCompletedNCT04809363Phase 4
• A Study of Kynteles Injection (Vedolizumab) in Adults With Moderate to Severe Ulcerative Colitis or Crohn's Disease or Chronic PouchitisCompletedNCT04799496
• Paricipant Preferences in the Treatment of Inflammatory Bowel Disease (IBD) in EuropeCompletedNCT04597905
• ENTYVIO in Bio-naive Patients With Moderate/Severe Crohn's Disease (CD) in Daily PracticeWithdrawnNCT04349449
• Health-Related Quality of Life in Crohn's Disease Participants With Complex Perianal Fistula Before and After TreatmentTerminatedNCT04102163
• Specified Drug-Use Survey on Vedolizumab for IV Infusion 300 mg [Crohn's Disease]CompletedNCT04002180
• A Study to Characterize Multidimensional Model to Predict the Course of Crohn's Disease (CD)CompletedNCT03668249
• A Study to Assess the Effectiveness and Safety of Treatment With Vedolizumab in Adult Participants With Ulcerative Colitis (UC) or Crohn's Disease (CD) in Real LifeTerminatedNCT03378388
• Sub-optimal Response to Anti-Tumor Necrosis Factor's in Inflammatory Bowel Disease in Emerging MarketsCompletedNCT03090139
• A Study to Observe the Safety and Efficacy of Vedolizumab in Biologically Naive Participants With Ulcerative Colitis (UC) or Crohn´s Disease (CD)CompletedNCT02986724
• Vedolizumab Subcutaneous (SC) Versus Intravenous (IV) in Ulcerative Colitis or Crohn's DiseaseWithdrawnNCT02913508Phase 2
• Phase 4, Vedolizumab-4002 Post-marketing, Disease-Drug-Drug Interaction StudyWithdrawnNCT02760615Phase 4
• OTIS Vedolizumab Pregnancy Exposure RegistryCompletedNCT02678052
• Entyvio (Vedolizumab) Long Term Safety StudyCompletedNCT02674308
• Adipose Derived Mesenchymal Stem Cells for Induction of Remission in Perianal Fistulizing Crohn's DiseaseCompletedNCT01541579Phase 3
• Safety and Efficacy of Adipose-Derived Stem Cells to Treat Complex Perianal Fistulas Patients With Crohn's DiseaseTerminatedNCT01378390Phase 3
• Study to Assess the Safety and Efficacy of Expanded Allogenic Adipose-derived Stem Cells (eASCs) (Cx601), for Treatment of Complex Perianal Fistulas in Perianal Crohn's Disease.CompletedNCT01372969Phase 1/2
• Phase 2 Study of the Safety and Efficacy of LDP-02 in Mildly to Moderately Active Crohn's PatientsCompletedNCT00655135Phase 2
• Safety and Efficacy of ALX-0600 in Subjects With Active Crohn's Disease Who Completed Protocol CL0600-008CompletedNCT00308438Phase 2
• Safety and Efficacy of ALX-0600 in Subjects With Active Crohn's DiseaseCompletedNCT00072839Phase 2